A5013824370- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Calcium signaling and nucleotide metabolism
- HIV/AIDS drug development and treatment
- Neuroendocrine Tumor Research Advances
- T-cell and Retrovirus Studies
- Cutaneous lymphoproliferative disorders research
- Ubiquitin and proteasome pathways
- Cancer Genomics and Diagnostics
- Ethics in Clinical Research
- Economic and Financial Impacts of Cancer
- Immunodeficiency and Autoimmune Disorders
Mayo Clinic in Florida
2016-2025
Jacksonville College
2015-2025
WinnMed
2015-2024
Texas Tech University Health Sciences Center
2024
Texas Tech University
2024
Jacksonville University
2024
Nemours Children’s Clinic
2022
Mayo Clinic Hospital
2021
Mayo Clinic in Arizona
2017-2020
Palmetto Hematology Oncology
2018
Rosai-Dorfman disease is a rare subtype of non-Langerhans cell histiocytosis. With the last major report published in 1990, there paucity contemporary data on this disease. Our objective was to clinicopathological features, treatments and outcomes patients seen at tertiary referral center. Sixty-four with histopathological diagnosis were identified from 1994 2017 (median age 50 years; range, 2-79). The median duration symptom onset seven months (range, 0-128), which also reflected number...
The purpose of the study was to describe clinicopathologic characteristics and clinical outcomes patients with primary breast angiosarcoma.The institutional database searched identify angiosarcoma seen between 1965 2002. Survival were estimated by Kaplan-Meier method. log-rank test used compare groups. Cox proportional hazards models for multivariate analysis.In all, 69 identified. Median follow-up 40 months (range, 0-413 months). age 46. tumor size at diagnosis 5.5 cm. Thirteen (18.8%)...
Studies of ethnic disparities in malignancies have revealed variation clinical outcomes. In multiple myeloma (MM), previous literature has focused only on patients Caucasian and African-American (AA) descent. We present a Surveillance Epidemiology End Results (SEER)-based outcome analysis MM from broader range ethnicities, representing current United States demographics. The SEER 17 Registry data was utilized to analyse adult diagnosed since 1992 (n = 37,963), as other ethnicities were not...
Abstract With improving survivorship in chronic lymphocytic leukemia (CLL), the risk of second primary malignancies (SPMs) has not been systematically addressed. Differences for SPMs among CLL survivors from Surveillance, Epidemiology, and End Results (SEER) database (1973–2015) were compared to individual expected general population. In ~270,000 person-year follow-up, 6487 new diagnosed with a standardized incidence ratio (SIR) 1.2 (95% CI:1.17–1.23). The higher was both solid (SIR 1.15;...
Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical trials. We report outcomes of 36 patients treated at Mayo Clinic. Our cohort received median eight prior lines therapy. Six belantamab combination with other medications (pomalidomide, cyclophosphamide, thalidomide), 13 (36%) were 70 years or older, two had creatinine >2.5 mg/dL, one...
Patients with chronic lymphocytic lymphoma (CLL) high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients disease. Relapsed/refractory CLL enrolled a phase II trial who had del(11q)(q22.3) del(17p)(p13.1) were included this analysis. received single agent for 21 days 4 week treatment cycle. The overall response rate among 38%, 19%...
Summary Lenalidomide has demonstrated impressive antileukaemic effects in patients with chronic lymphocytic leukaemia (CLL). The mechanism(s) by which it mediates these remain unclear. Clinically, CLL treated lenalidomide demonstrate an acute inflammatory reaction, the tumour flare reaction that is suggestive of immune activation phenomenon. Samples from were used to evaluate its effect on cell and components microenvironment (immune cellular cytokine). was unable directly induce apoptosis...
Summary Deubiquitinase enzymes ( DUB s) of the proteasomal 19S regulatory particle are emerging as important therapeutic targets in several malignancies. Here we demonstrate that inhibition two proteasome‐associated s USP 14 and UCHL 5) with small molecule inhibitor b‐ AP 15, results apoptosis human Waldenström macroglobulinaemia WM ) cell lines primary patient‐derived tumour cells. Importantly, 15 produced proteotoxic stress cells have acquired resistance to proteasome bortezomib. In silico...
BACKGROUND Outcomes have improved significantly in multiple myeloma (MM), but racial disparities health care access and survival exist. A comprehensive analysis exploring MM is warranted. METHODS Patients with from 1991 to 2010 the Surveillance, Epidemiology, End Results‐Medicare database were evaluated for trends clinical myeloma‐defining events (MDEs), receipt of treatment (drugs stem cell transplantation; [SCT]), cost care, overall (OS). RESULTS Among 35,842 patients, frequency all MDEs...
Introduction: Improving flu vaccination rates in the general population is an important and effective strategy toward reducing morbidity, mortality, cost of seasonal influenza. In order to optimize immunization strategies, factors associated with decreased need be explored. The literature suggests that there a gender difference rate influenza but limited population-based survey studies also inconsistent as which has higher vaccination. purpose this study was evaluate for gender-based among...
While immunotherapies, such as CAR T therapy and bi-specific antibodies, have revolutionized the treatment of multiple myeloma (MM), patients with AL amyloidosis been excluded from trials these agents due to concerns underlying autonomic, cardiac, renal dysfunction, leading potentially fatal toxicities therapies. In this communication, we described outcomes two concurrent MM cardiac and/or dysfunction who underwent anti-BCMA cell ide-cel or cilta-cel, received cytokine release syndrome...